Patients treated with a combination of trastuzumab and lapatinib who had wild-type PIK3CA obtained a total pathologic complete response ( pCR ) rate of 53.1 % , which decreased to 28.6 % in patients with tumors that carried PIK3CA activating mutations ( P = .012 ) .